While at UCLA, the company’s founder found the “Achilles heel” of flu virus, and has designed a superior influenza vaccine. Nearly all other universal flu vaccines in development will suffer from viral mutational escape, whereas InvVax has beaten this problem. Studies in mice have established the efficacy of our vaccine, and now InvVax is raising $500K in capital through a preferred equity financing to move the vaccine into preclinical trials.